Suven Life Sciences

    SUVEN
    Pharma
    ₹265.65
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹7,506 Cr

    P/E
    13.73
    Day range
    ₹263.45 – ₹270.00
    52-week range
    ₹124.11 – ₹403.35
    Volume
    1.41 L
    Open
    ₹269.00
    Prev close
    ₹268.65

    Latest results · Q2 FY27(consolidated)Revenue ₹1 Cr+30.4%Profit ₹-107 CrMargin -8922.3%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Promoter holding falling

      65.47%, down 4.68 pts since 2026-03-06 · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 32 / 100

    Factor percentiles

    Value36
    Quality20
    Momentum57
    Low volatility16

    Derived metrics

    Earn. yield
    7.3%
    ROE ÷ P/B
    -4.7%
    12-1 mom.
    +62.0%
    Return / vol
    0.75
    Magic Formula
    #389
    Piotroski
    2/6
    FCF yield
    -4.0%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Suven Life SciencesSUVEN₹7,506 Cr13.7316.81-78.7%-80.0%-9242.0%0.040.0%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 10h ago

    Headlines about Suven Life Sciences from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    Price / Book
    16.60
    ROE (FY26)
    -78.7%
    ROCE (latest year)
    -80%
    Dividend yield
    0.00%

    Moving averages (NSE)

    20-day
    ₹269.66
    Price below
    50-day
    ₹303.11
    Price below
    200-day
    ₹255.5
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    -20.6%
    Revenue YoY (Sep 2026)
    +0.0%
    Operating margin
    -9242.0%
    Net margin
    -10700.0%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    -150 Cr-100 Cr-50 Cr0 Cr50 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026-10000%-5000%0%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • DII
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-500 Cr0 Cr500 Cr1K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26-150%-100%-50%0%50%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr200 Cr400 Cr600 Cr800 Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY15FY16FY17FY18FY19₹0₹0.5₹1₹1.5₹2

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales221321213241
    YoY Sales growth-18-8-73-16-34-38—-64————
    Expenses493332554145538110652136112
    Operating Profit-46-30-31-52-39-44-51-80-103-51-132-111
    OPM %-1885%-1267%-3024%-2032%-2435%-2981%-2714%-8671%-3678%-3331%-3711%-9242%
    Other Income644421143787
    Interest000000000000
    Depreciation221121111222
    Profit before tax-42-28-28-50-39-44-52-77-102-46-128-107
    Tax %0%-4%0%0%0%0%0%0%0%0%0%0%
    Net Profit-42-27-28-50-39-44-52-77-102-46-128-107
    EPS in Rs₹-1.91₹-1.22₹-1.29₹-2.28₹-1.79₹-2.01₹-2.36₹-3.40₹-4.48₹-1.73₹-4.83₹-3.78

    From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days78

    +30 days since Mar 2021

    Inventory Days—
    Days Payable—
    Cash Conversion Cycle78

    +30 days since Mar 2021

    Working Capital Days506

    -578 days since Mar 2021

    Strengths, risks & growth

    Suven Life Sciences is a clinical-stage biopharmaceutical company developing proprietary New Chemical Entities for central nervous system disorders. Its five clinical assets target agitation in Alzheimer’s dementia, narcolepsy, major depressive disorder and cognitive disorders. [1] [2]

    Strengths

    • Company is almost debt free.

    Risks

    • Stock is trading at 16.7 times its book value
    • Company has low interest coverage ratio.
    • Promoter holding has decreased over last quarter: -4.61%
    • The company has delivered a poor sales growth of -12.0% over past five years.
    • Company has a low return on equity of -65.9% over last 3 years.
    • Debtor days have increased from 63.7 to 77.5 days.
    • Working capital days have increased from 55.6 days to 506 days

    Compounded Sales Growth

    10 Years
    -35%
    5 Years
    -12%
    3 Years
    -19%
    TTM
    +55%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    —
    3 Years
    —
    TTM
    -80%

    Stock Price CAGR

    10 Years
    +38%
    5 Years
    +25%
    3 Years
    +47%
    1 Year
    +48%

    Return on Equity

    10 Years
    -24%
    5 Years
    -68%
    3 Years
    -66%
    Last Year
    -82%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter67.36%70.15%70.08%65.47%-4.61 pp
    FII1.07%0.91%0.56%0.45%-0.11 pp
    DII3.39%4.62%2.93%2.17%-0.76 pp
    Public28.18%24.32%26.42%31.89%+5.47 pp

    Filed with NSE for Sept 2026: promoters 65.47%, public 34.53%

    Analysts & fund holdings

    Valuation vs Pharmaceuticals
    P/E13.7 vs 45.1
    Sector P/B6.03
    Beta1.33

    Who holds the shares, quarter by quarter

    Mutual funds 0.08% (+0.07 pp)
    Dec 25
    Mar 26
    Jun 26
    Jul 26
    Aug 26
    Sept 26
    • Promoters65.5%
    • Foreign institutions0.5%
    • Mutual funds0.1%
    • Insurance0.0%
    • Other domestic institutions2.1%
    • Retail17.7%
    • Others14.2%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Motilal Oswal Nifty Microcap 250 Index Fund0.07%0.24%+0.24 pp
    Groww Nifty Total Market Index Fund0.00%0.01%+0.01 pp
    Bandhan BSE Healthcare Index Fund0.00%0.12%-0.02 pp
    Aditya Birla SL BSE Total Market Index Fund0.00%0.01%+0.01 pp
    Motilal Oswal BSE 1000 Index Fund0.00%0.01%-0.00 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Low
    Profitability
    Low
    Entry point
    Avg
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    55.6%
    Downside volatility
    45.0%
    Worst 5% of days
    4.6%
    Average of that tail
    5.9%
    Max drawdown (1Y)
    45.5%
    Below its peak
    32.2%

    Against the market

    Beta vs Nifty 50
    1.22
    Correlation
    0.30
    Relative strength (3M)
    -24.1%
    ATR (14)
    5.0%

    Return

    Return 1M
    -12.5%
    Return 3M
    -20.2%
    Return 6M
    +5.2%
    Return 1Y
    +41.8%
    vs 200-day average
    +4.0%

    Momentum

    RSI (14)
    41.1
    MACD histogram
    2.02
    Stochastic %K
    25.1
    ADX (14)
    16.9
    +DI / −DI
    17.5 / 20.5
    Money flow index
    54.4

    Participation

    Delivery (20d avg)
    41.1%
    vs its 60-day baseline
    -1.6 pts
    Volume vs 20-day
    -1.3σ
    Close vs day's VWAP
    -0.1%
    52-week position
    52 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    2 of 6 tested

    • Return on assets positive — failed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — failed
    Free cash flow
    -₹306 Cr
    FCF yield
    -4.0%
    Cash conversion
    1.09
    Accruals ratio
    0.040
    Net debt
    -₹8 Cr
    Net debt / equity
    -0.02
    EV / sales
    833.91
    Capex intensity
    71.4%
    Revenue CAGR
    30.4%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net buying ₹426 Cr
    1 buys · ₹426 Cr
    0 sells · ₹0
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Jasti Property and Equity Holdings Private Limited
    Promoter Group · Conversion of security
    Buy3,17,68,764₹426 Cr10 Mar 2026

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • other
      Not available — not reported in this filing

      Annual General Meeting

      30 Jul 2024
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      2 Aug 2023
      ex-date
    • rights
      Not available — not reported in this filing

      Rights 1:2 @ Premium Rs 54/-

      17 Oct 2022
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      29 Jul 2022
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      2 Aug 2021
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      11 Sept 2020
      ex-date
    • other
      Not available — not reported in this filing

      Demerger

      21 Jan 2020
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      8 Aug 2019
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      14 Feb 2019
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      9 Aug 2018
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share (Purpose Revised)

      6 Feb 2018
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      9 Aug 2017
      ex-date
    • dividend
      Not available — not reported in this filing

      Interim Dividend Re 1 Per Share

      8 Feb 2017
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      4 Aug 2016
      ex-date
    • dividend
      Not available — not reported in this filing

      Interim Dividend - Re 1/- Per Share / Special Dividend - Re 1/- Per Share (Purpose Revised)

      14 Mar 2016
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting/Dividend - Re 0.60/- Per Share

      23 Jul 2015
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting /Final Dividend - Re 0.50/- Per Share + Special Dividend - Rs 2/- Per Share

      24 Jul 2014
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting / Dividend - Re.0.30/- Per Equity Share

      1 Aug 2013
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting And Dividend Re.0.30 Per Share

      17 Sept 2012
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting And Dividend Re.0.25 Per Share

      1 Aug 2011
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)

    Please find enclosed the Revised News Release of our company

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Please find enclosed the News Release of our Company

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Please find enclosed News Release of our Company

    Company Update
    Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    Monitoring Agency Report for the quarter ended 30th September, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper publication on Un-audited financial results

    Result
    Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September 2026

    Un-audited financial results for the quarter and half year ended 30th September 2026

    Board Meeting
    Board Meeting Outcome for Board Meeting Outcome For Un-Audited Financial Results For The Quarter And Half Year Ended September 30, 2026

    Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Consideration Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended 30Th September, 2026

    Suven Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Unaudited financial results ....

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Special Window for Re-lodgment of transfer requests of Physical shares

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018

    Insider Trading / SAST
    Closure of Trading Window
    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Please find enclosed the News release

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Report of Scrutinizer

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Outcome of 37th Annual General Meeting

    Company Update
    Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    Monitoring Agency Report for the quarter ended 30th June, 2026

    Filed with BSE (scrip 530239); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Regulatory orders

    • Adjudication order

      Adjudication Order in respect of Suven Life Sciences Limited and 5 others in the matter of Suven Life Sciences Limited

      28 Oct 2021
      Read on SEBI
    • Order

      Order in the matter of Suven Life Sciences Ltd.

      27 Apr 2021
      Read on SEBI

    Documents

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 5 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Suven Life Sciences: common questions

    Answered from the figures on this page.

    Suven Life Sciences last traded at ₹265.65 (NSE, as of 18 Nov 2026). The last session moved it down 1.12%.

    Suven Life Sciences is valued at about ₹7,506 crore (NSE, as of 18 Nov 2026).

    Suven Life Sciences trades at a price-to-earnings ratio of 13.73 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Suven Life Sciences has traded between ₹124.11 and ₹403.35 over the past 52 weeks, to 18 Nov 2026. It is currently 51% of the way up that range.

    Suven Life Sciences (SUVEN) is classified under Pharma on this site's screener.